Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives.
Despite overwhelming evidence of the benefits of risk-adjusted oral anticoagulation on stroke reduction in patients with atrial fibrillation (AF), there is still considerable undertreatment. A multidisciplinary expert group was formed to discuss issues surrounding anticoagulant treatment of patients...
| Main Authors: | , , , , , , , , , , |
|---|---|
| פורמט: | Journal article |
| שפה: | English |
| יצא לאור: |
2009
|
| _version_ | 1826281759679971328 |
|---|---|
| author | Levi, M Hobbs, F Jacobson, A Pisters, R Prisco, D Bernardo, A Haas, M Heidrich, J Rosenberg, M Nielsen, J Wuillemin, W |
| author_facet | Levi, M Hobbs, F Jacobson, A Pisters, R Prisco, D Bernardo, A Haas, M Heidrich, J Rosenberg, M Nielsen, J Wuillemin, W |
| author_sort | Levi, M |
| collection | OXFORD |
| description | Despite overwhelming evidence of the benefits of risk-adjusted oral anticoagulation on stroke reduction in patients with atrial fibrillation (AF), there is still considerable undertreatment. A multidisciplinary expert group was formed to discuss issues surrounding anticoagulant treatment of patients with AF to try and achieve consensus on various aspects of the implementation of guidelines on oral anticoagulation therapy in AF. Panel members were cardiologists, hematologists, and laboratory and primary care physicians with specific expertise from Europe and the United States. One of the most important conclusions of the meeting was to enhance guideline adherence by better communication of the data showing that the benefits of stroke reduction outweigh the risk of bleeding associated with treatment with vitamin K antagonists. Management of oral anticoagulation therapy by dedicated centers, such as anticoagulation clinics, or by patient self-management may improve the quality of anticoagulation and facilitate the management of these patients and thereby further facilitate optimal antithrombotic management in patients with AF. |
| first_indexed | 2024-03-07T00:33:39Z |
| format | Journal article |
| id | oxford-uuid:80abaaf2-919b-4c28-8a37-e584b2f5525d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:33:39Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:80abaaf2-919b-4c28-8a37-e584b2f5525d2022-03-26T21:24:52ZImproving antithrombotic management in patients with atrial fibrillation: current status and perspectives.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:80abaaf2-919b-4c28-8a37-e584b2f5525dEnglishSymplectic Elements at Oxford2009Levi, MHobbs, FJacobson, APisters, RPrisco, DBernardo, AHaas, MHeidrich, JRosenberg, MNielsen, JWuillemin, WDespite overwhelming evidence of the benefits of risk-adjusted oral anticoagulation on stroke reduction in patients with atrial fibrillation (AF), there is still considerable undertreatment. A multidisciplinary expert group was formed to discuss issues surrounding anticoagulant treatment of patients with AF to try and achieve consensus on various aspects of the implementation of guidelines on oral anticoagulation therapy in AF. Panel members were cardiologists, hematologists, and laboratory and primary care physicians with specific expertise from Europe and the United States. One of the most important conclusions of the meeting was to enhance guideline adherence by better communication of the data showing that the benefits of stroke reduction outweigh the risk of bleeding associated with treatment with vitamin K antagonists. Management of oral anticoagulation therapy by dedicated centers, such as anticoagulation clinics, or by patient self-management may improve the quality of anticoagulation and facilitate the management of these patients and thereby further facilitate optimal antithrombotic management in patients with AF. |
| spellingShingle | Levi, M Hobbs, F Jacobson, A Pisters, R Prisco, D Bernardo, A Haas, M Heidrich, J Rosenberg, M Nielsen, J Wuillemin, W Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. |
| title | Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. |
| title_full | Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. |
| title_fullStr | Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. |
| title_full_unstemmed | Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. |
| title_short | Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. |
| title_sort | improving antithrombotic management in patients with atrial fibrillation current status and perspectives |
| work_keys_str_mv | AT levim improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives AT hobbsf improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives AT jacobsona improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives AT pistersr improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives AT priscod improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives AT bernardoa improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives AT haasm improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives AT heidrichj improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives AT rosenbergm improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives AT nielsenj improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives AT wuilleminw improvingantithromboticmanagementinpatientswithatrialfibrillationcurrentstatusandperspectives |